13, 14 e 21

/ NOV

TRANSMISSÕES AO VIVO DE 8H ÀS 13H

1st International Symposium on Minimal Treatment and Breast Imaging 

Belo Horizonte   |   Minas Gerais   |   Brasil

PRINCIPAIS TEMAS ABORDADOS

PALESTRANTES CONVIDADOS INTERNACIONAIS

Ruud Pijnappel

MD, PhD, Prof., Radiologist

Nisha Sharma

MBChB, BSB(Hons), MRCP, FRCR, MSC

Henry Mark Kuerer

MD, PhD, CMQ, FACS

FAÇA SUA INSCRIÇÃO EVENTO GRATUITO PARA MÉDICOS

E ASSOCIADOS SBM
ATÉ
31/06/2020
ATÉ
31/08/2020
ATÉ
31/10/2020
NO LOCAL
01/11/2020
MÉDICO

Todas as Especialidades

Gratuito Gratuito Gratuito Gratuito
RESIDENTE E
PÓS-GRADUANDOS
Associado SBM
Gratuito Gratuito Gratuito Gratuito
RESIDENTES E
PÓS-GRADUANDOS
Não Associados
R$ 200,00 R$ 250,00 R$ 300,00 R$ 350,00
ESTUDANTES DE
GRADUAÇÃO
R$ 100,00 R$ 125,00 R$ 150,00 R$ 200,00
OUTROS
PROFISSIONAIS
R$ 450,00 R$ 500,00 R$ 550,00 R$ 600,00

PROGRAMA PRELIMINAR SUJEITO A ALTERAÇÕES PROGRAMAÇÃO CIENTÍFICA

08:00 - 08:05

OPENING

08:05 – 09:35

ROUND 1

IN SITU DUCTAL CARCINOMA (DISC)

08:05 - 08:25:
Low Grade in situ ductal carcinoma, is it a risk or precursor lesion? Prognosis and risk of underestimation on needle biopsy.

08:25 - 08:45:
Overdiagnosis and Overtreatment – How big is the problem?

08:45 - 09:05:
Genetic signature for CDIS – Is it time for Radiotherapy omission?

09:05 - 09:25:
Indolent Lesions of Epitelial Origen (IDLE)

09:25 - 09:35:
Discussion

09:35 – 10:00

CONFERENCE

RESULTS AND APPLICATION OF CESM AS A BREAST IMAGING PROBLEM SOLVING TOOL AND IN EVALUATING PATIENTS FOR MINIMAL TREATMENT.

Speaker: Ruud Pijnappel (Holland)

10:00 – 10:05

10:00 – 10:05:
Discussion

10:05 – 10:30

CONFERENCE

ADVANCED BREAST INTERVENTIONS.

Speaker: Ruud Pijnappel (Holland)

10:30 – 10:35

10:30 – 10:35:
Discussion

10:35 – 11:00

CONFERENCE

DUCTAL IN SITU CARCINOMA AND ACTIVE SURVEILLANCE: RISKS, SECURITY, METHODS OF SAMPLE AND DIAGNOSES.

Speaker: Ruud Pijnappel (Holland)

11:00 – 11:05

11:00 – 11:05:
Discussion

11:05 – 13:00

ROUND 2

IMAGING

11:05 – 11:25:
Artificial intelligence for breast cancer screening, automated breast US, and the future of breast image.

11:25 – 11:45:
Personalized Breast Cancer Screening.

11:45 – 12:05:
Breast Cancer Screening of women of high and intermediated risk.

12:05 – 12:25:
Breast image and molecular types of breast cancer – Is there reasonable correlation?

12:25 – 12:45:
When is it possible to suspect tumor heterogeneity and repeat breast biopsy?

12:45 – 13:00:
Discussion

08:00 - 08:05

OPENING

08:05 – 09:15

ROUND 3

LESIONS OF UNCERTAIN MALIGNANT POTENTIAL (B3 LESIONS)

08:05 - 08:25:
Lesions of uncertain malignant potential (B3 lesions). Why is a simple core biopsy not enough for secure diagnose? Can Immunohistochemistry substitute the complete excision of the lesion? Vacuum Assisted Biopsy (VAB) and Vacuum Assisted Excision (VAE) pathological analyses and report how I do.

08:25 - 08:45:
Imaging B3 Lesions – Is it possible to select for VAB and VAE upfront?

08:45 - 09:05:
B3 lesions – VAE as the new gold standard – Is it reduces the diagnostic surgeries?

09:05 - 09:15:
Discussion

09:15 – 09:40

CONFERENCE

THE PRACTICAL ISSUES IN IMPLEMENTING Contrasted Enhanced Spectral Mamography (CESM) IN CLINICAL PRACTICE AND WHERE IS IT OF BENEFIT?

Speaker: Nisha Sharma (United Kingdom)

09:40 – 10:05

CONFERENCE

THE EXPANDING ROLE OF VAE FROM B3 LESIONS TO INVASIVE CANCERS.

Speaker: Nisha Sharma (United Kingdom)

10:05 – 10:20

10:05 – 10:20:
Discussion

10:20 – 11:30

ROUND 4

SURGICAL MINIMAL TREATMENT FOR BREAST CANCER.

10:20- 10:40:
Percutaneous Treatment: Resection technics - Where are we?

10:40 - 11:00:
Cryoablation – Where are we?

11:00 - 11:20:
Robotic surgery for breast cancer – Is it time for?

11:20 – 11:30:
Discussion

11:30 – 13:00

ROUND 5

NEW PARADIGMAS FOR BREAST CANCER TREATMENT

11:30 – 11:50:
Personalized and precision medicine: a new paradigm breast cancer treatment.

11:50 – 12:10:
Rational use for prognostic genetic signature

12:10 – 12:30:
Genetic prognostic signatures for planning surgical treatment.

12:30 – 12:50:
Hereditary genetic panel, Is it for every breast cancer patient?

12:50 – 13:00:
Discussion

08:00 - 08:05

OPENING

08:05 – 09:55

08:05 - 08:25:
Evolution of systemic treatment and future perspectives

08:25 - 08:45:
Neoadjuvant chemotherapy as a new gold standard of treatment.

08:45 - 09:05:
Pathological Complete Response and its meaning.

09:05 - 09:25:
Contrasted Enhanced Spectral Mammography and MRI for predict and evaluate neoadjuvant chemotherapy response of breast cancer.

09:25 - 09:45:
Response adjusted therapy and surgery for breast cancer

09:45 - 09:55:
Discussion

09:55 – 10:55

ROCHE SYMPOSIUM

10:55 – 11:15

CONFERENCE

EVALUATING PCR AFTER NST: IMAGING, CORE NEEDLE, VACUUM BIOPSY, IS THERE SOMETHING CAN YOU RELY ON AND ITS CONSEQUENCES?

Speaker: Henry M. Kuerer (USA)

11:15 – 11:35

CONFERENCE

SELECTIVE OMISSION OF AXILLARY NODE DISSECTION FOR NODE POSITIVE BREAST CANCER AFTER NEOADJUVANT SYSTEMIC THERAPHY – IS IT POSSIBLE NOW OR IN NEAR FUTURE?

Speaker: Henry M. Kuerer (USA)

11:35 – 11:50

11:35 – 11:50:
Discussion

11:50 – 13:00

ROUND 6

SELECTIVE OMISSION OF AXILLARY SURGERY .

11:50 – 12:10:
Sentinel node biopsy for luminal breast cancers after menopause, Is it necessary?

12:10 – 12:30:
US and assisted minimally invasive diagnostic procedures of axilla– How is it to deal with the data?

12:30 – 12:50:
Do genetic prognostic signatures help in omission axillary surgery?

12:50 – 13:00:
Discussion

LOCAL DO EVENTO

CENTRO DE CONVENÇÕES DA ASSOCIAÇÃO MÉDICA DE MINAS GERAIS

Avenida João Pinheiro, 161, Centro

Belo Horizonte – MG

Como chegar

FAÇA SUA INSCRIÇÃO EVENTO GRATUITO PARA MÉDICOS

E ASSOCIADOS SBM

ASSINE NOSSA NEWSLETTER

RECEBA EM PRIMEIRA MÃO TODAS INFORMAÇÕES SOBRE O EVENTO

CIRURGIAS COMENTADAS POR Superespecialistas

REALIZAÇÃO

PATROCINADOR DIAMANTE

PATROCINADOR OURO

APOIO